Inspra

Eplerenone, the active ingredient in Inspra, is an aldosterone antagonist presented as an oral formulation for oral use. It is employed to manage hypertension and to improve outcomes in patients with heart failure, particularly those with reduced ejection fraction. By selectively blocking aldosterone receptors in the distal nephron, it promotes sodium excretion while conserving potassium, contributing to blood pressure reduction and cardiac remodeling mitigation.

GNH USA supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inspra, an aldosterone antagonist, is used in cardiovascular conditions where aldosterone excess contributes to disease progression. - Hypertension: lowers blood pressure by promoting natriuresis and potassium retention. - Heart failure: reduces risk of hospitalization and mortality in patients with reduced ejection fraction. - Post‑myocardial infarction: helps lower the incidence of cardiovascular events in patients with left‑ventricular dysfunction.

Eplerenone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hyperkalaemia: elevated serum potassium levels. - Dizziness or light‑headedness, especially on standing. - Diarrhoea or gastrointestinal upset. - Headache. - Fatigue. - Nausea.

Serious or Rare Side Effects: - Severe hyperkalaemia leading to cardiac arrhythmia. - Acute renal impairment or worsening kidney function. - Angioedema or severe allergic reactions. - Hepatic dysfunction or elevated liver enzymes. - Life‑threatening hypotension. - Myocardial infarction in susceptible patients.

Before initiating Inspra, clinicians should consider several safety measures. - Monitor serum potassium: check levels regularly to avoid hyperkalaemia. - Assess renal function: evaluate creatinine and eGFR before and during therapy. - Use caution in patients with diabetes mellitus, as they may have altered potassium handling. - Avoid in severe hepatic impairment due to reduced metabolism. - Adjust dose in elderly patients or those with moderate renal dysfunction. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Eplerenone can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Potassium‑sparing diuretics (e.g., amiloride, triamterene): risk of severe hyperkalaemia. - ACE inhibitors or ARBs: additive potassium increase and renal effects. - Potassium supplements: may precipitate dangerous hyperkalaemia. - NSAIDs: can impair renal function and raise potassium levels.

Moderate Interactions (Monitor Closely): - Digoxin: altered serum levels due to electrolyte shifts. - Thiazide diuretics: may counteract potassium‑retaining effect. - Lithium: risk of lithium toxicity with altered renal clearance. - Beta‑blockers: may enhance hypotensive response. - Anticoagulants (e.g., warfarin): monitor INR as potassium changes can affect clotting parameters.